Aviragen Therapeutics Announces Rescheduled Date and Time of Fourth Quarter and Fiscal Year 2016 Financial Results on Septemb...
September 13 2016 - 7:00PM
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota
Pharmaceuticals, Inc.), a pharmaceutical company that is developing
the next generation of antivirals, today announced that management
will host a conference call on Wednesday, September 14, 2016 at
4:30 p.m. ET to review the Company’s financial results for the
three month period and 2016 fiscal year ended June 30, 2016 and
will provide an update on recent corporate developments. The
Company will issue a press release summarizing its financial
results the same day, prior to the conference call.
In order to participate in the conference call,
please dial (877) 312-5422 (domestic) or (253) 237-1122
(international) and refer to conference ID number 74878442. The
live webcast can be accessed under the Investors section of the
Company’s website at www.aviragentherapeutics.com.
About Aviragen Therapeutics,
Inc.
Aviragen Therapeutics is focused on the
discovery and development of the next generation of direct-acting
antivirals to treat infections that have limited therapeutic
options and affect a significant number of patients globally. The
Company has three product candidates in active clinical
development: vapendavir, an oral treatment for human rhinovirus
upper (HRV) respiratory infections in moderate-to-severe asthmatics
currently being evaluated in the Phase 2b SPIRITUS trial; BTA585,
an oral fusion protein inhibitor that has received Fast Track
designation by the U.S. FDA, in Phase 2 development for
the treatment and prevention of respiratory syncytial virus (RSV)
infections; and BTA074, a topical antiviral treatment in Phase 2
development for condyloma caused by human papillomavirus types 6
& 11. For additional information about the Company, please
visit www.aviragentherapeutics.com.
Contacts:
Mark Colonnese
Executive Vice President and Chief Financial Officer
Aviragen Therapeutics, Inc.
(678) 221-3381
mcolonnese@aviragentherapeutics.com
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024